Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.54 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL808799 | 0.82 | DGAT1 (0.74) | DGAT1ELANEKCNN4ALDH1A1SRC | |
| SCHEMBL27905901 | 0.79 | DGAT1 (0.70) | DGAT1ELANEKCNN4ALDH1A1SRC | |
| Ammonia Solution, Strong SCHEMBL7639328 | 0.79 | DGAT1 (0.70) | DGAT1ELANEKCNN4ALDH1A1SRC | |
| SCHEMBL23091415 | 0.79 | DGAT1 (0.70) | DGAT1ELANEKCNN4ALDH1A1SRC | |
| Iodide SCHEMBL10533676 | 0.79 | DGAT1 (0.70) | DGAT1ELANEKCNN4ALDH1A1SRC | |
| SCHEMBL1464979 | 0.79 | DGAT1 (0.50) | DGAT1ELANEKCNN4ALDH1A1 | |
| SCHEMBL18269834 | 0.78 | DGAT1 (0.42) | DGAT1KCNN4ALDH1A1SRC | |
| SCHEMBL20257642 | 0.77 | DGAT1 (0.48) | DGAT1ELANEKCNN4 | |
| SCHEMBL5859056 | 0.77 | DGAT1 (0.59) | DGAT1ELANEKCNN4ALDH1A1SRC | |
| SCHEMBL808933 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230154-A1 | COMPOUND HAVING SHP2 PROTEIN DEGRADING ACTIVITY, AND MEDICAL USES THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2025-07-17 | — | — | US | disclosed |
| EP-4385991-A1 | COMPOUND HAVING SHP2 PROTEIN DEGRADING ACTIVITY, AND MEDICAL USES THEREOF | Ubix Therapeutics, Inc. (KR) | 2024-06-19 | — | — | EP | disclosed |
| CN-117881678-A | Compound with SHP2 protein degradation activity and medical application thereof | 尤比克斯治疗公司 | 2024-04-12 | — | — | CN | disclosed |
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2023086352-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20230151019-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2023018155-A1 | COMPOUND HAVING SHP2 PROTEIN DEGRADING ACTIVITY, AND MEDICAL USES THEREOF | 주식회사 유빅스테라퓨틱스 | 2023-02-16 | — | — | WO | disclosed |
| WO-2020071798-A1 | COMPOUND, COLORED RESIN COMPOSITION, COLOR FILTER, AND DISPLAY DEVICE | 동우 화인켐 주식회사 | 2020-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230154-A1 | COMPOUND HAVING SHP2 PROTEIN DEGRADING ACTIVITY, AND MEDICAL USES THEREOF | PTPN1, PTPN5, PTPN2 | DGAT1 2063/4885ELANE 1787/4885KCNN4 4792/4885 |
| US-20230151019-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, PKD1 | DGAT1 3619/4885ELANE 3860/4885KCNN4 474/4885 |
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, PKD1 | DGAT1 3863/4885ELANE 3520/4885KCNN4 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.